Fulcrum Therapeutics Inc
NASDAQ:FULC
Intrinsic Value
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one FULC stock under the Base Case scenario is 3.06 USD. Compared to the current market price of 7.06 USD, Fulcrum Therapeutics Inc is Overvalued by 57%.
Valuation Backtest
Fulcrum Therapeutics Inc
Run backtest to discover the historical profit from buying and selling FULC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fulcrum Therapeutics Inc
Current Assets | 242.2m |
Cash & Short-Term Investments | 236.2m |
Receivables | 2.2m |
Other Current Assets | 3.7m |
Non-Current Assets | 15.5m |
PP&E | 12.4m |
Other Non-Current Assets | 3.1m |
Current Liabilities | 13.7m |
Accounts Payable | 2.8m |
Accrued Liabilities | 10.5m |
Other Current Liabilities | 396k |
Non-Current Liabilities | 8.8m |
Other Non-Current Liabilities | 8.8m |
Earnings Waterfall
Fulcrum Therapeutics Inc
Revenue
|
2.8m
USD
|
Operating Expenses
|
-113.5m
USD
|
Operating Income
|
-110.7m
USD
|
Other Expenses
|
13.3m
USD
|
Net Income
|
-97.3m
USD
|
Free Cash Flow Analysis
Fulcrum Therapeutics Inc
What is Free Cash Flow?
FULC Profitability Score
Profitability Due Diligence
Fulcrum Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Fulcrum Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
FULC Solvency Score
Solvency Due Diligence
Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FULC Price Targets Summary
Fulcrum Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for FULC is 13.52 USD with a low forecast of 5.05 USD and a high forecast of 19.95 USD.
Ownership
FULC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FULC Price
Fulcrum Therapeutics Inc
Average Annual Return | -4.1% |
Standard Deviation of Annual Returns | 43.58% |
Max Drawdown | -93% |
Market Capitalization | 437.1m USD |
Shares Outstanding | 61 935 200 |
Percentage of Shares Shorted | 4.51% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
Contact
IPO
Employees
Officers
The intrinsic value of one FULC stock under the Base Case scenario is 3.06 USD.
Compared to the current market price of 7.06 USD, Fulcrum Therapeutics Inc is Overvalued by 57%.